|Dr. John M. Maraganore||CEO & Exec. Director||1.79M||5.77M||1963|
|Mr. Barry E. Greene||Pres||1M||4.27M||1963|
|Mr. Jeffrey V. Poulton||Exec. VP, CFO and Principal Financial & Accounting Officer||681.75k||N/A||1968|
|Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA||Chief Operating Officer||1.14M||453.27k||1963|
|Dr. Akshay K. Vaishnaw||Pres of R&D||986.1k||N/A||1963|
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 6; Compensation: 2.